Press Enter to search · Esc to close
A new wave of 2025 research suggests semaglutide and its siblings do far more than shrink waistlines. The evidence is moderate, the implications are not.
New 2025 data hints that GLP-1 drugs may quiet inflammation in the liver and skin — but a sober pharmacology review reminds us the price tag, and the science, are still catching up.
Two fresh analyses push the GLP-1 conversation past nausea, flagging ear-nose-throat signals and a higher risk of failed bowel prep. Here's what tired parents juggling a new prescription actually need to know.
New survey and claims data suggest a quiet mismatch in cardiometabolic care: physicians may be undercounting how much weight and risk these drugs move, while many eligible adults never start them.
Beyond fat loss and blood sugar, GLP-1 receptor agonists are stacking evidence in failing hearts, rare obesity syndromes, Alzheimer's, and even bone. Here's what's real — and what's still hype.
A phase 3 Parkinson's trial, a kidney meta-analysis, an ocular cohort and new mechanistic work suggest the GLP-1 class is becoming a multi-system intervention — with important caveats.
Phase III data on IcoSema and fresh SURMOUNT analyses of tirzepatide are rewriting what 'best-in-class' looks like for metabolic and obesity care.
The dual GIP/GLP-1 agonist is moving past weight loss into lipid repair and intracranial pressure relief. But a small case series flags a risk off-label users haven't been warned about.
GLP-1 receptor agonists are sprawling past diabetes and obesity into cardiovascular protection, body-composition debates, and pill-form delivery. Here is what the latest wave of evidence supports — and what it doesn't.
As weekly injections become a fixture of the looksmaxing toolkit, anesthesiologists are raising a quieter alarm about what happens when patients carrying a slow-emptying stomach meet an operating table.